Disclosures for "Remibrutinib, a Novel Bruton’s Tyrosine Kinase Inhibitor, Exhibits Improved Target Selectivity and Potency In Vitro")
-
Bernd C. Kieseier, MD has nothing to disclose.
-
Mr. Cenni has received personal compensation for serving as an employee of Novartis.
-
Dr. Pulz has received personal compensation for serving as an employee of Novartis Pharma AG. Dr. Pulz has stock in Novartis Pharma AG.
-
Dr. Angst has received personal compensation for serving as an employee of Novartis. Dr. Angst has stock in Novartis.
-
Mr. Eichlisberger has nothing to disclose.
-
Dr. Ziehn has received personal compensation for serving as an employee of Novartis AG.